Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T18:30:55.959Z.
Calculation as of: 2026-10-06T18:30:55.959Z.
Quote observation: 2026-10-06T18:29:58.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6abed0f02887b3ac62520bc322e243c8ff06f4fcddd7c97914d2a236e2670171
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$321.62M
EV/EBIT Ratio
34.51x
TTM Avg
44.92x
3Y Avg
44.92x
5Y Avg
44.92x
Market Cap
$302.45M
EV/EBIT Ratio
N/A
TTM Avg
23.87x
3Y Avg
23.87x
5Y Avg
23.87x
Market Cap
$303.90M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ClearPoint Neuro, Inc. (CLPT) | $323.14M | N/A | N/A | N/A | N/A |
| Cabaletta Bio, Inc. (CABA)vs › | $322.03M | N/A | N/A | N/A | N/A |
| Sanara MedTech Inc. (SMTI)vs › | $321.62M | 34.51x | 44.92x | 44.92x | 44.92x |
| CapsoVision, Inc. (CV)vs › | $325.26M | N/A | N/A | N/A | N/A |
| Avita Medical Inc. (RCEL)vs › | $320.22M | N/A | N/A | N/A | N/A |
| Agenus Inc. (AGEN)vs › | $320.23M | 9.45x | 35.72x | 35.72x | 18.31x |
| C4 Therapeutics, Inc. (CCCC)vs › | $312.35M | N/A | N/A | N/A | N/A |
| Benitec Biopharma Inc. (BNTC)vs › | $302.45M | N/A | 23.87x | 23.87x | 23.87x |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $303.90M | N/A | N/A | N/A | N/A |
| Relmada Therapeutics, Inc. (RLMD)vs › | $348.23M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute